Zynerba Pharmaceuticals Announces that Results from Phase 2 STOP Trial Support Continued Development of ZYN002 in Osteoarthritis

14/8/2017 8:30

Conference Call Zynerba Pharmaceuticals Inc

Zynerba Pharmaceuticals Inc Conference call will be held on Aug 14, 2017. During the earnings conference call's session Zynerba Pharmaceuticals Inc will provide updated information and financial status.
Conference call is also referred to as: teleconference call or audio conference bridge. Conferencing service is provided in house or as cloud based teleconference service.
In order to join the audio conferencing dial conference bridge and key in the PIN code, Contact Zynerba Pharmaceuticals Inc for this information
Schedule an online conference with QCONF conference service and get 5 free calls with online conferencing.
Unless the context indicates otherwise, the terms "Zynerba," "Zynerba Pharmaceuticals," "we," "us," "our," "our company" and "our business" refer to Zynerba Pharmaceuticals, Inc. Company Overview We are a specialty pharmaceutical company focused on developing and commercializing proprietary next­generation synthetic cannabinoid therapeutics formulated for transdermal delivery. We are evaluating two patent­protected product candidates, ZYN002 and ZYN001, in five indications. We intend to study ZYN002 in patients with refractory epilepsy, osteoarthritis, or OA, and Fragile X syndrome, or FXS. We intend to study ZYN001 in patients with fibromyalgia and peripheral neuropathic pain. We believe these product candidates will provide new treatment options for patients, as well as additional treatment options for patients not currently receiving adequate relief from current treatment regimens.    
Read more Conference Call

Zynerba Pharmaceuticals Inc (ZYNE)

80 West Lancaster Avenue, Devon Pennsylvania 19333, United States